Category: Crypto Hub

Posted on by — Leave a comment

XRPUSD News Today, Nov 23: Predicting XRP’s Future Value with Bold Pro – Meyka

Acquiring insight into the future value of XRPUSD is crucial for investors navigating the unpredictable waters of cryptocurrency. Recent forecasts for XRP hover between conservative predictions of £16 by 2030 to exceedingly daring estimates of £800, rising to heights of nearly £3,850. Intense interest stems from expected institutional adoption and Ripple’s ongoing legal dramas. Currently priced at £1.58, XRPUSD is facing a daily dip of 2.3%. As we explore XRP’s potential, we’ll unpack key market indicators and expert opinions.
When discussing XRP price prediction, analysts provide a wide scope of possibilities. Conservative estimates suggest XRP could reach £16 by 2030, a figure driven largely by Ripple’s firm position in cross-border payment solutions. More optimistic forecasts see the cryptocurrency reaching between £800 and nearly £3,850. Such bullish predictions are fueled by a potential increase in institutional adoption and expected regulatory clarity.
Ripple’s ongoing legal battle against the U.S. Securities and Exchange Commission (SEC) is a significant factor. A favorable outcome could unlock new growth pathways for XRP. Regardless of the eventual legal ruling, Ripple continues to secure partnerships that strengthen its ecosystem, further boosting long-term investor confidence.
A closer look at XRPUSD’s technical indicators reveals a challenging environment. The Relative Strength Index (RSI) stands at 33.77, suggesting oversold conditions. However, an ADX of 36.77 indicates a strong trend presence, despite negative momentum seen through a MACD of -0.14.
Bollinger Bands show price volatility, with the current rate near its lower band. The Awesome Oscillator reflects a bearish short-term outlook. Nevertheless, a growing market interest, marked by an MFI of 22.62, hints at potential shifts. Investors should consider these aspects carefully when evaluating their positions.
Institutional adoption plays a crucial role in XRP’s trajectory. Ripple’s strategic alliances with financial institutions continue to bring credibility and new operational use cases to XRP.
The resolution of Ripple’s legal challenges could be pivotal. If Ripple successfully defends against SEC charges, it may bolster XRP, potentially leading to significant price appreciation. Whether these positive developments will materialize remains speculative, but their impact on XRP’s value is undeniable. This anticipation keeps investor interest intact, aligning with the evident growth in XRPUSD’s long-term potential.
Here’s a closer look at potential future scenarios for XRP in 2030.
The future of XRPUSD involves a complex interplay of legal, industry, and market forces. Predicted values ranging from £16 to over £3,850 demonstrate the wide spectrum of possibilities. Institutional uptake and the pending legal resolution are two critical facets that could drive substantial changes in XRP’s value.
For investors, it’s vital to monitor these developments attentively. Each passing event shapes the market’s predictions and the cryptocurrency landscape as a whole. As always, conducting detailed analysis and staying informed will be key to navigating these waters effectively.
Meyka, an AI-driven platform, offers real-time financial insights and predictive analytics to assist investors in making informed decisions amidst such volatility.
As of now, XRPUSD trades at £1.58. It experienced a daily decline of 2.3% but remains up 295% year-over-year, reflecting significant volatility and growth potential.
Ripple’s legal battles with the SEC significantly influence XRP’s price. A positive ruling could unlock new growth opportunities, while a negative outcome might hinder its market expansion.
Long-term predictions for XRP vary widely, from £16 to upwards of £3,850 by 2030. These estimates account for potential institutional adoption and legal outcomes affecting its usage and demand.
Get instant AI-powered stock research, analysis, and market insights 24/7 from our research platform.
AI analysis and forecasts for mentioned stocks
Subscribe to our newsletter for market insights, AI predictions, and updates on our latest tools delivered to your inbox.
What makes our chatbot and platform famous among traders
Meyka AI analyzes social chatter, news, and alternative data to reveal hidden stock opportunities before mainstream market reports catch up.
Meyka AI delivers machine learning stock forecasts, helping investors anticipate price movements with precision across multiple timeframes.
Meyka AI’s proprietary grading algorithm ranks stocks A+ to F, giving investors unique insights beyond traditional ratings.
Backtest trading strategies with Meyka AI’s chatbot, analyzing historical performance and risk instantly.
Get instant AI-powered earnings summaries for any stock or by specific dates through our intelligent chatbot with real-time data processing.
Join thousands of traders using our advanced AI tools for smarter investment decisions
Meyka is the best Alternative Data platform powered by AI providing research insights for investors
The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

source

Posted on by — Leave a comment

FLUID Insights: Wintermute's Role in the Crypto Market and Emerging Trends – OKX

Looks like you're in the United States. Switch to the United States site for products available in your region.
Trading instruments
Powerful tools
Wintermute is a leading algorithmic trading firm and market maker in the cryptocurrency space. Renowned for providing liquidity across over 50 exchanges and trading platforms, Wintermute plays a pivotal role in ensuring efficient trading and price stability in the volatile crypto market. This article explores Wintermute's activities, its impact on the broader market, and emerging trends shaping the future of decentralized finance (DeFi).
Wintermute's on-chain activity highlights its strategic approach to navigating the evolving crypto landscape. The firm has demonstrated a keen ability to adapt to market conditions, particularly in its interactions with centralized exchanges (CEXs). Following major events like the FTX collapse, Wintermute has adjusted its trading strategies to mitigate risks and maintain liquidity.
Since early 2023, Wintermute's trading activity with major CEXs, including Binance, Coinbase, Kraken, and OKX, has experienced a noticeable decline. Binance remains Wintermute's most utilized CEX, but trading flows have reduced significantly since May 2023. This trend aligns with a broader market-wide decline in trading volumes, driven by increasing regulatory scrutiny and waning investor confidence.
Key events such as the FTX collapse and the LUNA crash have profoundly influenced Wintermute's trading strategies. For instance, during the $19 billion crypto liquidation event in 2025, Wintermute temporarily paused trading to reassess its risk exposure. These actions underscore the firm's rules-based approach to trading and its commitment to mitigating risks during periods of extreme market volatility.
One of the most debated aspects of Wintermute's operations is its use of the 'loan option model.' This practice involves tokens being loaned to market makers, which can sometimes lead to price manipulation and token dumps. While this model provides liquidity, it has also sparked significant controversy within the crypto community.
The 'loan option model' has raised ethical and regulatory concerns. Critics argue that it disproportionately benefits market makers at the expense of smaller crypto projects, often resulting in sharp token price crashes. As regulatory bodies increasingly scrutinize such practices, the crypto industry may see significant changes in market-making operations. These developments could reshape the balance between liquidity provision and ethical trading practices.
Wintermute has demonstrated its adaptability by diversifying into decentralized platforms, showcasing its commitment to innovation within the DeFi ecosystem. This strategic shift highlights the firm's forward-thinking approach to staying relevant in a rapidly evolving market.
One notable example of Wintermute's diversification is its involvement in OutcomeMarket, a decentralized prediction market focused on events like the 2024 U.S. presidential election. This venture underscores Wintermute's interest in exploring new opportunities within the DeFi space, further solidifying its position as a market leader.
Wintermute has also ventured into operating dark automated market makers (AMMs), such as Tessera V. These dark AMMs prioritize trade execution over transparency, offering traders improved liquidity management. This innovation reflects a growing demand for advanced DeFi tools and highlights the shifting priorities of traders seeking better execution in a competitive market.
Wintermute's strategic decisions and trading patterns have far-reaching implications for the broader crypto market. As a major liquidity provider, any changes in its activity can influence market dynamics, including price stability and trading volumes. Additionally, its cautious approach to avoiding insolvent exchanges underscores the importance of risk management in the volatile crypto landscape.
Despite facing criticism for certain practices, Wintermute has also demonstrated the potential for ethical market-making. Successful projects that have benefited from Wintermute's support highlight the possibility of fostering a healthier and more sustainable crypto ecosystem. These case studies serve as a blueprint for balancing liquidity provision with ethical considerations.
Wintermute continues to play a pivotal role as a market maker and liquidity provider in the cryptocurrency industry. From its controversial 'loan option model' to its innovative ventures into decentralized platforms like OutcomeMarket and Tessera V, the firm remains at the forefront of the crypto market's transformation. As the industry matures, Wintermute's strategies and practices will likely shape the future of trading and liquidity in both centralized and decentralized ecosystems.

source

Posted on by — Leave a comment

Ethnobotanical medicine is effective against the bacterium causing Lyme disease – Frontiers

A preclinical study in test tubes showed that selected plant-based herbal medicines, especially Ghanaian quinine and Japanese knotweed, work better than antibiotics. Image: Shutterstock.
— by Mischa Dykstra
Lyme disease, also called borreliosis, is the most common vector-borne disease in the Northern hemisphere. It is caused by the spirochete (corkscrew-shaped) bacterium Borrelia burgdorferi and close relatives and mainly spread through the bite of infected ticks.
Currently, more than 300,000 new cases are reported in the USA each year, compared to 65,000 in Europe, and these numbers are rising due to climate change and urban sprawl. The standard of care for Lyme disease, a course of antibiotics over 2-4 weeks, is not always effective: at least 10-20% of treated patients continue to experience symptoms after treatment. Late-stage Lyme patients may experience many different symptoms, including fatigue, joint pains, memory problems, facial paralysis, aches, stiffness in the neck, heart palpitations, and severe headaches. The discovery of novel treatments against Lyme disease is therefore of great interest.
Evaluation of Natural and Botanical Medicines for Activity against Growing and Non-growing Forms of B. burgdorferi► Read original article► Download original article (pdf)
In a new study published in Frontiers in Medicine, researchers from the Johns Hopkins Bloomberg School of Public Health, with colleagues at the California Center for Functional Medicine and Focus Health, surveyed the power of 14 plant-based extracts to kill Borrelia burgdorferi, compared to the currently used Lyme antibiotics doxycycline and cefuroxime.
The researchers tested these extracts’ effectiveness in vitro (outside of a living organism) against the free-swimming "planktonic" form of the bacterium as well as against microcolonies. Microcolonies are aggregates of bacteria, the first stage in the development of biofilms – structured bacterial communities that stick to a surface and are embedded in a slimy extracellular matrix.
The researchers show that plant extracts from black walnut, cat's claw, sweet wormwood, Mediterranean rockrose, and Chinese skullcap had strong activity against B. burgdorferi, outperforming both tested antibiotics.
But by far the strongest performers were Ghanaian quinine (Cryptolepis sanguinolenta; also known as yellow-dye root, nibima, or kadze) and Japanese knotweed (Polygonum cuspidatum).
Ghanaian quinine is a shrub from West Africa containing the antimicrobial alkaloid cryptolepine, and is used in ethnomedicine to treat malaria, hepatitis, septicemia, and tuberculosis. Japanese knotweed is a traditional medicine in India and China that contains the polyphenol resveratrol. In other preclinical studies it has been found to have anti-tumor and anti-inflammatory effects and protect the nervous system and heart. Extracts from both plants were found to kill microcolonies of Borrelia burgdorferi and inhibit division of the planktonic form, even at low concentrations (0.03-0.5%). Remarkably, a single 7-day treatment with 1% Ghanaian quinine could completely eradicate the bacterium – it did not regrow, even under optimal conditions in the drug's absence.
“This study provides the first convincing evidence that some of the herbs used by patients such as Cryptolepis, black walnut, sweet wormwood, cat's claw, and Japanese knotweed have potent activity against Lyme disease bacteria, especially the dormant persister forms, which are not killed by the current Lyme antibiotics,” says Dr Ying Zhang from the Johns Hopkins Bloomberg School of Public Health.
Related: An innovative new diagnostic for Lyme disease
“These findings are exciting as they offer opportunities for improved treatment of persistent Lyme disease, which is not helped by the current standard treatment. We are interested in further evaluating these potent herbal medicines through animal studies as well as clinical trials.”
However, not all tested compounds or herbs yielded positive results against the bacterium. Extracts of grapefruit seeds, green chiretta, ashwagandha, candy leaf (also known as stevia), fuller's teasel, and Japanese teasel had little or no effect_,_ and neither did the chemicals colloidal silver, monoglyceride monolaurin, or antimicrobial peptide LL37 from human immune cells. This was surprising, as anecdotal and preclinical studies suggested that they might be effective, and they are often used in the community of Lyme disease practitioners and patients.
“Many thousands of Lyme patients today, especially those with later-stage symptoms who have not been effectively treated, are in great need of efficacious, accessible treatment options,” says Dr Sunjya K. Schweig, CEO and co-Director of the California Center for Functional Medicine and Scientific Advisory Board Member of the Bay Area Lyme Foundation.
Coauthor Jacob Leone of the FOCUS Health Group stresses: “Patients and their clinicians are increasingly turning to herbal remedies as additional treatment options, and we hope that these findings will help point the way toward a greater understanding of these therapies. But further preclinical studies and clinical trials will be required to establish evidence for effective treatment of Lyme disease patients.”
This research was supported by the Bay Area Lyme Foundation and the Steven & Alexandra Cohen Foundation.
Original article: Evaluation of Natural and Botanical Medicines for Activity against Growing and Non-growing Forms of B. burgdorferi
February 21, 2020
Share on WeChat
Scan with WeChat to share this article
Get the latest research updates, subscribe to our newsletter

source

Posted on by — Leave a comment

Seven herbal medicines can kill Lyme disease bacteria in test tube – LymeDisease.org

Researchers have determined that seven herbal medicines are highly active in test tubes against B. burgdorferi, the bacteria that causes Lyme disease, compared to the control antibiotics, doxycycline and cefuroxime.
Published in the journal Frontiers in Medicine, the laboratory study was funded by the Bay Area Lyme Foundation and supported in part by The Steven & Alexandra Cohen Foundation.
Researchers at Johns Hopkins Bloomberg School of Public Health and colleagues at the California Center for Functional Medicine and FOCUS Health Group, Naturopathic collaborated on the study.
“Since traditional antibiotic approaches fail to resolve symptoms in up to 25% of patients treated for Lyme disease and many suffer disabling effects of the disease, there is a need for novel treatment proven effective against B. burgdorferi,” said the paper’s co-author Sunjya K. Schweig, MD, CEO and co-director, California Center for Functional Medicine and Scientific Advisory Board Member, Bay Area Lyme Foundation.
“Because patients are currently turning to herbal remedies to fill the treatment gaps left by antibiotics, this research is a critical step in helping clinicians, as well as patients, understand which ones may offer the most potential benefit.”
According to this study, carried out by Prof. Ying Zhang’s group at the Johns Hopkins Bloomberg School of Public Health, the seven herbal medicines that have the ability to kill B. burgdorferi in test tubes are:
It is important to note that each of these products have the potential to produce significant side effects in patients, and should be taken only under advisement of a clinician knowledgeable of their capabilities and toxicities.
Of these products, the Cryptolepis sanguinolenta extract caused complete eradication, while doxycycline and cefuroxime and other active herbs did not. This extract has been used for the treatment of malaria as well as the tick-borne infection Babesia, a malaria-like parasite.
This study is believed to be the first time this extract has been documented to have a potential impact on B. burgdorferi, and additional laboratory and clincial studies should be conducted to investigate the potential role Cryptolepis sanguinolenta could play in the treatment of Lyme disease.
Further, Cryptolepis sanguinolenta and Polygonum cuspidatum (Japanese knotweed) showed strong activity against both growing B. burgdorferi (MIC=0.03%-0.06% and 0.25%-0.5% respectively) and non-growing stationary phase B. burgdorferi.
In contrast, Stevia rebaudiana, Andrographis paniculata, Grapefruit seed extract, colloidal silver, monolaurin, and antimicrobial peptide LL37 had little or no activity against stationary phase B. burgdorferi.
“Our hope is that findings from this study could point to new therapeutic options for doctors and their patients, and pave the way for clinical research to help patients with persistent Lyme disease,” said Linda Giampa, executive director, Bay Area Lyme Foundation.
These data may provide a basis for the clinical improvement of patients who take herbal medicines, particularly those whose chronic symptoms may be due to persistent bacteria that are not killed by conventional Lyme antibiotic treatment.
However, it is critical to note that additional studies are needed to further evaluate the seven active botanical medicines identified in the study. Patients should not attempt to self-treat with these herbal medicines due to potential side effects and lack of clinical trials with these products.
For the study, the researchers tested 14 natural products in test tubes against B. burgdorferi. Plant extracts selected for the study included herbs or agents that: have been previously used to manage the symptoms of patients who do not respond to standard Lyme antibiotic treatment; have favorable safety profiles; and can be absorbed systemically.
Additional criteria for selecting compounds included anti-biofilm effects and ability to cross the blood-brain barrier. To conduct the study, the plant extracts in concentrations of 1%, 0.5% and 0.25% and antibiotic controls were each tested on growing as well as non-growing B. burgdorferi cultures.
The study found that seven of these natural product extracts at 0.25%-0.5% had better activity against the stationary phase B. burgdorferi culture than the control antibiotics doxycycline and cefuroxime, both of which are commonly used to treat Lyme disease.
The paper titled “Evaluation of Natural and Botanical Medicines for Activity against Growing and Non-growing Forms of B. burgdorferi,” was written by Jie Feng, PhD, Jacob Leone, ND, Sunjya Schweig, MD, and Ying Zhang, MD, PhD.
PRESS RELEASE SOURCE: Bay Area Lyme Foundation
LymeDisease.org is a non-profit
501(c)(3) that serves the patient community through advocacy, education and research.
Federal EIN-68-0214101
Support LymeDisease.org
Become a member.
Comments? Questions?
Ask your questions here.
LymeDisease.org
PO Box 16009 | San Diego, CA 92176

source